NCT06402175

Brief Summary

The pattern of hematological malignancies (HMs) in developing countries and developed countries differs. Among the different types of cancers, leukemia, lymphoma, and multiple myeloma appear to have greatly increased in frequency.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
10mo left

Started Jul 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress67%
Jul 2024Apr 2027

First Submitted

Initial submission to the registry

April 20, 2024

Completed
17 days until next milestone

First Posted

Study publicly available on registry

May 7, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

June 5, 2024

Status Verified

June 1, 2024

Enrollment Period

2.7 years

First QC Date

April 20, 2024

Last Update Submit

June 4, 2024

Conditions

Haematologic Neoplasm

Outcome Measures

Primary Outcomes (1)

  • overall survival rate

    Assessment of overall survival of hematological malignancies at Assiut university Hospital * Estimate rate of non-relapse mortality. * Estimate rate of complete remission. * Estimate rate of refractory disease. * Estimate the rate of relapsed diseases.

    5 years

Interventions

follow upOTHER

follow up

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

follow up of hematological malignancy

You may qualify if:

  • Adult patients of Hematological malignancies (≥18 years)

You may not qualify if:

  • patients who have started diagnosis and treatment for malignancy outside Assiut university.
  • Age less than 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer

Study Record Dates

First Submitted

April 20, 2024

First Posted

May 7, 2024

Study Start

July 1, 2024

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

April 1, 2027

Last Updated

June 5, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share